Advertisement

Topics

AACR 2018: Updated data for durvalumab plus tremelimumab for NSNSCLC

10:00 EDT 17 Apr 2018 | ecancermedicalscience

Efficacy and safety data from two Phase I trials evaluating durvalumab in combination with tremelimumab in 2nd-line immunotherapy-naïve patients with either non-squamous advanced non-small cell lung cancer (NSCLC) (Study 006) or metastatic urothelial...

Original Article: AACR 2018: Updated data for durvalumab plus tremelimumab for NSNSCLC

NEXT ARTICLE

More From BioPortfolio on "AACR 2018: Updated data for durvalumab plus tremelimumab for NSNSCLC"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Biological Therapy
Biological therapy involves the use of living organisms, substances derived from living organisms, or laboratory-produced versions of such substances to treat disease. Some biological therapies for cancer use vaccines or bacteria to stimulate the body&rs...

Gilotrif (afatinib)
GILOTRIF (afatinib) is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L8...